Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
51 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2014', provides an overview of the Metastatic Transitional Cell Cancer (Urothelial Cell Cancer)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Transitional Cell Cancer (Urothelial Cell Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Overview 6 Therapeutics Development 7 Pipeline Products for Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Overview 7 Pipeline Products for Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Comparative Analysis 8 Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Therapeutics under Development by Companies 9 Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Products under Development by Companies 12 Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Companies Involved in Therapeutics Development 13 Astellas Pharma Inc. 13 Merck & Co., Inc. 14 Novartis AG 15 Sumitomo Dainippon Pharma Co., Ltd. 16 Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 amrubicin hydrochloride - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 buparlisib hydrochloride - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 enfortumab vedotin - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 pembrolizumab - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 SNX-5422 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Recent Pipeline Updates 40 Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Dormant Projects 49 Appendix 50 Methodology 50 Coverage 50 Secondary Research 50 Primary Research 50 Expert Panel Validation 50 Contact Us 51 Disclaimer 51
List of Tables Number of Products under Development for Metastatic Transitional Cell Cancer (Urothelial Cell Cancer), H2 2014 7 Number of Products under Development for Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Late Stage Development, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Products under Development by Companies, H2 2014 12 Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Astellas Pharma Inc., H2 2014 13 Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Merck & Co., Inc., H2 2014 14 Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Novartis AG, H2 2014 15 Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 16 Assessment by Monotherapy Products, H2 2014 17 Number of Products by Stage and Target, H2 2014 19 Number of Products by Stage and Mechanism of Action, H2 2014 21 Number of Products by Stage and Route of Administration, H2 2014 23 Number of Products by Stage and Molecule Type, H2 2014 25 Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics - Recent Pipeline Updates, H2 2014 40 Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Dormant Projects, H2 2014 49
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.